Skip to main content
Erschienen in: Strahlentherapie und Onkologie 12/2012

01.12.2012 | Original article

Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function

verfasst von: M. Hata, MD, I. Koike, J. Maegawa, A. Kaneko, K. Odagiri, T. Kasuya, Y. Minagawa, H. Kaizu, Y. Mukai, T. Inoue

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Surgical excision remains the standard and most reliable curative treatment for eyelid carcinoma, but frequently causes functional and cosmetic impairment of the eyelid. We therefore investigated the efficacy and safety of radiation therapy in eyelid carcinoma.

Patients and methods

Twenty-three patients with primary carcinoma of the eyelid underwent radiation therapy. Sebaceous carcinoma was histologically confirmed in 16 patients, squamous cell carcinoma in 6, and basal cell carcinoma in 1. A total dose of 50–66.6 Gy (median, 60 Gy) was delivered to tumor sites in 18–37 fractions (median, 30 fractions).

Results

All but 3 of the 23 patients had survived at a median follow-up period of 49 months. The overall survival and local progression-free rates were 87% and 93% at 2 years, and 80% and 93% at 5 years, respectively. Although radiation-induced cataracts developed in 3 patients, visual acuity in the other patients was relatively well preserved. There were no other therapy-related toxicities of grade 3 or greater.

Conclusion

Radiation therapy is safe and effective for patients with primary carcinoma of the eyelid. It appears to contribute to prolonged survival as a result of good tumor control, and it also facilitates functional and cosmetic preservation of the eyelid.
Literatur
1.
Zurück zum Zitat Berenbom A, Davila RM, Lin HS et al (2007) Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye 21:1198–1201PubMedCrossRef Berenbom A, Davila RM, Lin HS et al (2007) Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye 21:1198–1201PubMedCrossRef
2.
Zurück zum Zitat Cook BE Jr, Bartley GB (1999) Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted Country, Minnesota. Ophthalmology 106:746–750PubMedCrossRef Cook BE Jr, Bartley GB (1999) Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted Country, Minnesota. Ophthalmology 106:746–750PubMedCrossRef
3.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef
4.
Zurück zum Zitat Ejima Y, Sasaki R, Okamoto Y et al (2006) Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol 78:6–9PubMedCrossRef Ejima Y, Sasaki R, Okamoto Y et al (2006) Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol 78:6–9PubMedCrossRef
5.
Zurück zum Zitat Fitzpatrick PJ, Thompson GA, Easterbrook WM et al (1984) Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys 10:449–454PubMedCrossRef Fitzpatrick PJ, Thompson GA, Easterbrook WM et al (1984) Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys 10:449–454PubMedCrossRef
6.
Zurück zum Zitat Hata M, Koike I, Omura M et al (2012) Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys 82:605–611PubMedCrossRef Hata M, Koike I, Omura M et al (2012) Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys 82:605–611PubMedCrossRef
7.
Zurück zum Zitat Hendley RL, Rieser JC, Cavanagh HD et al (1979) Primary radiation therapy for meibomian gland carcinoma. Am J Ophthalmol 87:206–209PubMed Hendley RL, Rieser JC, Cavanagh HD et al (1979) Primary radiation therapy for meibomian gland carcinoma. Am J Ophthalmol 87:206–209PubMed
8.
Zurück zum Zitat Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
9.
Zurück zum Zitat Kniestedt C, Stamper RL (2003) Visual acuity and its measurement. Ophthalmol Clin North Am 16:155–170PubMedCrossRef Kniestedt C, Stamper RL (2003) Visual acuity and its measurement. Ophthalmol Clin North Am 16:155–170PubMedCrossRef
10.
Zurück zum Zitat Kuhnt T, Klockenbrink U, Knipping S et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187:292–299PubMedCrossRef Kuhnt T, Klockenbrink U, Knipping S et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187:292–299PubMedCrossRef
11.
Zurück zum Zitat Kumar R (2010) Clinicopathologic study of malignant eyelid tumors. Clin Exp Optom 93:224–227PubMedCrossRef Kumar R (2010) Clinicopathologic study of malignant eyelid tumors. Clin Exp Optom 93:224–227PubMedCrossRef
12.
Zurück zum Zitat Lentrodt J (1977) Principles of the surgical therapy of eyelid tumours. J Maxillofac Surg 5:93–107PubMedCrossRef Lentrodt J (1977) Principles of the surgical therapy of eyelid tumours. J Maxillofac Surg 5:93–107PubMedCrossRef
13.
Zurück zum Zitat Lin HY, Cheng CY, Hsu WM et al (2006) Incidence of eyelid cancers in Taiwan: a 21-year review. Ophthalmology 113:2101–2107PubMedCrossRef Lin HY, Cheng CY, Hsu WM et al (2006) Incidence of eyelid cancers in Taiwan: a 21-year review. Ophthalmology 113:2101–2107PubMedCrossRef
14.
Zurück zum Zitat Moesen I, Duncan M, Cates C et al (2011) Nitrous oxide cryotherapy for primary periocular basal cell carcinoma: outcome at 5 years follow-up. Br J Ophthalmol 95:1679–1681PubMedCrossRef Moesen I, Duncan M, Cates C et al (2011) Nitrous oxide cryotherapy for primary periocular basal cell carcinoma: outcome at 5 years follow-up. Br J Ophthalmol 95:1679–1681PubMedCrossRef
15.
Zurück zum Zitat Mombaerts I, Gillis A (2010) The tunneled forehead flap in medial canthal and eyelid reconstruction. Dermatol Surg 36:1118–1125PubMedCrossRef Mombaerts I, Gillis A (2010) The tunneled forehead flap in medial canthal and eyelid reconstruction. Dermatol Surg 36:1118–1125PubMedCrossRef
16.
Zurück zum Zitat Nunery WR, Welsh MG, McCord CD Jr (1983) Recurrence of sebaceous carcinoma of the eyelid after radiation therapy. Am J Ophthalmol 96:10–15PubMed Nunery WR, Welsh MG, McCord CD Jr (1983) Recurrence of sebaceous carcinoma of the eyelid after radiation therapy. Am J Ophthalmol 96:10–15PubMed
17.
Zurück zum Zitat Pardo FS, Wang CC, Albert D et al (1989) Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys 17:643–647PubMedCrossRef Pardo FS, Wang CC, Albert D et al (1989) Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys 17:643–647PubMedCrossRef
18.
Zurück zum Zitat Petsuksiri J, Frank SJ, Garden AS et al (2008) Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 112:111–118PubMedCrossRef Petsuksiri J, Frank SJ, Garden AS et al (2008) Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 112:111–118PubMedCrossRef
19.
Zurück zum Zitat Rades D, Meyners T, Kazic N et al (2011) Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. A matched-pair analysis. Strahlenther Onkol 187:541–547PubMedCrossRef Rades D, Meyners T, Kazic N et al (2011) Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. A matched-pair analysis. Strahlenther Onkol 187:541–547PubMedCrossRef
20.
Zurück zum Zitat Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef
21.
Zurück zum Zitat Reading VM, Weale RA (1993) Self-administered automatic sight-testing. A feasibility study. Doc Ophthalmol 83:43–54PubMedCrossRef Reading VM, Weale RA (1993) Self-administered automatic sight-testing. A feasibility study. Doc Ophthalmol 83:43–54PubMedCrossRef
22.
Zurück zum Zitat Rosa J, Casal D, Moniz P (2010) Upper eyelid reconstruction with a horizontal V-Y myotarsocutaneous advancement flap. J Plast Reconstr Aesthet Surg 63:2013–2017PubMedCrossRef Rosa J, Casal D, Moniz P (2010) Upper eyelid reconstruction with a horizontal V-Y myotarsocutaneous advancement flap. J Plast Reconstr Aesthet Surg 63:2013–2017PubMedCrossRef
23.
Zurück zum Zitat Russell HC, Chadha V, Lockington D et al (2010) Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 94:1316–1321PubMedCrossRef Russell HC, Chadha V, Lockington D et al (2010) Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 94:1316–1321PubMedCrossRef
24.
Zurück zum Zitat Swanson MW, Cloud G (1991) A retrospective analysis of primary eye cancer at the University of Alabama 1958–1988. Part 2: eyelid tumors. J Am Optom Assoc 62:820–823PubMed Swanson MW, Cloud G (1991) A retrospective analysis of primary eye cancer at the University of Alabama 1958–1988. Part 2: eyelid tumors. J Am Optom Assoc 62:820–823PubMed
25.
Zurück zum Zitat Takamura H, Yamashita H (2005) Clinicopathological analysis of malignant eyelid tumor cases at Yamagata University Hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol 49:349–354PubMedCrossRef Takamura H, Yamashita H (2005) Clinicopathological analysis of malignant eyelid tumor cases at Yamagata University Hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol 49:349–354PubMedCrossRef
26.
27.
Zurück zum Zitat Wolff HA, Bosch J, Jung K et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef Wolff HA, Bosch J, Jung K et al (2010) High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 186:262–268PubMedCrossRef
Metadaten
Titel
Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function
verfasst von
M. Hata, MD
I. Koike
J. Maegawa
A. Kaneko
K. Odagiri
T. Kasuya
Y. Minagawa
H. Kaizu
Y. Mukai
T. Inoue
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 12/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0145-9

Weitere Artikel der Ausgabe 12/2012

Strahlentherapie und Onkologie 12/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.